Courtesy of Steve Sanders:
There are numerous vagus nerve stimulators on the market - used for depression, epilepsy, migraines, obesity (some analysts say the market for weight loss will be the biggest market over the next few years - bigger than AI) and numerous other multi-billion dollar conditions. Most are implanted, but not all. They all seem to work on the same principal as Actipatch/RecoveryRx, and most are FDA approved but not covered by insurance.
It seems everyone should be wearing an Actipatch/RecoveryRx on their vagus nerve, especially considering the recent patent application for chronic inflammation (such as cardiovascular problems -supplement/replace cholesterol meds/blood thinners?). Standard of Care!
Problem is it can't be advertised for these conditions without FDA approval, and that will take years, even with a partner like Medtronic.
Only way to use it for these conditions, immediately, is "off label" and as a "wellness product" - by people using it and discovering it works, then letting others know (word-of-mouth grass roots marketing). Best way to do that, once again, is by employing a direct sellers strategy for the US market.
I was really surprised that the PR for the latest patent application did not emphasize the implications for humans more. Chronic inflammation is huge and makes the NPA look like lunch money. Might want to consider releasing another PR that catches the attention of the medical and investment community. Medtronic would probably be knocking at the door with a $100 million check by the end of the day (don't take it!).
Copilot
BioElectronics Corporation’s Innovative Patent Application: A Leap Forward in Chronic Inflammation Treatment
BioElectronics Corporation is excited to announce the filing of a pivotal utility patent application, numbered 18/667,971, which marks a significant step forward in the battle against chronic systemic inflammation—a condition that afflicts over one-third of Americans. This patent application is the collaborative achievement of John Martinez, Kenneth McLeod, PhD, and Richard Staelin, PhD, and introduces a non-invasive method to combat a widespread health issue that affects a vast number of people.
The patent application encompasses a variety of methods, systems, apparatuses, and devices that are designed to modulate the immune response by non-invasively stimulating the vagal nerves. This approach is supported by the encouraging results of a double-blind, placebo-controlled canine study, which validated the effectiveness of Pulsed Short Wave Therapy (PSWT) Technology in significantly alleviating systemic discomfort associated with chronic diseases.
Chronic systemic inflammation is a prevalent concern in healthcare, often managed with lifestyle adjustments and anti-inflammatory drugs, which can be burdensome and have significant side effects. BioElectronics’ patent application introduces a groundbreaking technique that capitalizes on the inflammatory reflex, offering the potential to change the way chronic inflammation is treated.
AI
